Life Science Intelligence Blog

Stroke is the second largest cause of death globally, claiming an estimated 5.5 million lives annually. The burden of stroke is expected to worsen in the future as a result of demographic and lifestyle changes in developed and developing countries. During the acute stage there are several pharmaceuticals and surgical procedures available to assist healthcare providers manage stroke patients. This market research report provides forecasts and analysis of the embolization products used in the management and treatment of stroke. In addition to market forecasts, this report provides insights into the leading competitors in the cerebral embolization products market.

The ambitious goal for healthcare in Brazil is “health for all”. Formed in 1988, Brazil’s Sistema Único da Saúde (SUS) is one of the largest public health systems in the world. Universal healthcare in Brazil is funded through local and federal taxes provided by government and private institutions. The SUS ensures that Brazilian residents and foreigners in Brazil have access to public healthcare. It is estimated that 75% of Brazil’s 200+ million residents is reliant on the SUS for access to healthcare.

Healthcare in Europe parallels the US healthcare system in many ways. Western Europe faces significant challenges when it comes to determining how to efficiently meet the demand for more healthcare to an aging population with an increasing burden of age-related chronic diseases. Simultaneously, the issues of how to keep costs down and affordable to patients continues to test the healthcare sector in the five major European markets (France, Germany, Italy, Spain, United Kingdom). However, these problems are not unique to the five largest economies in Europe. These challenges pervade all countries within the European Union.

The United States is the largest healthcare market in the world. Boasting the third largest population (~330 million people) and a well-developed healthcare system, the US remains the key market to target for the commercialization of healthcare solutions.

Healthcare in China is in a constant state of reform as the system evolves to meet the unique burdens of the country which rapidly became the world’s second largest economy. With a population of approximately 1.4 billion people, demand for healthcare services is at an all-time high in China, with many hospitals understaffed and overwhelmed by demand.

Substantial increases in surgical procedure volumes are being projected across most medical segments as a result of a number of factors, including but not limited to: